Laura E. Horvath

693 total citations
15 papers, 526 citations indexed

About

Laura E. Horvath is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Laura E. Horvath has authored 15 papers receiving a total of 526 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Genetics. Recurrent topics in Laura E. Horvath's work include Acute Myeloid Leukemia Research (2 papers), CAR-T cell therapy research (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Laura E. Horvath is often cited by papers focused on Acute Myeloid Leukemia Research (2 papers), CAR-T cell therapy research (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Laura E. Horvath collaborates with scholars based in United States, United Kingdom and Japan. Laura E. Horvath's co-authors include James N. Atkins, Gary K. Schwartz, Howard S. Höchster, Heinz‐Josef Lenz, Monica M. Bertagnolli, Eileen M. O’Reilly, Bert H. O’Neil, Briant Fruth, Donna Niedzwiecki and Richard L. Schilsky and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Laura E. Horvath

15 papers receiving 513 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laura E. Horvath United States	8	337	226	143	96	72	15	526
Jong Seok Lee South Korea	12	215 0.6×	146 0.6×	108 0.8×	96 1.0×	56 0.8×	18	478
Kazım Uygun Türkiye	15	312 0.9×	215 1.0×	98 0.7×	155 1.6×	50 0.7×	56	683
Anwar Giryes Switzerland	12	374 1.1×	180 0.8×	48 0.3×	133 1.4×	55 0.8×	21	602
Jennifer A. Dorth United States	15	371 1.1×	272 1.2×	115 0.8×	248 2.6×	76 1.1×	60	837
Esra Kaytan Türkiye	10	240 0.7×	189 0.8×	115 0.8×	174 1.8×	54 0.8×	18	480
Viktor Gruenwald Germany	14	236 0.7×	368 1.6×	124 0.9×	65 0.7×	121 1.7×	53	586
Renjian Jiang United States	16	406 1.2×	220 1.0×	80 0.6×	209 2.2×	151 2.1×	61	689
Pier Paolo Fattori Italy	10	275 0.8×	253 1.1×	104 0.7×	74 0.8×	86 1.2×	24	642
Geraldine Goss Australia	13	452 1.3×	494 2.2×	153 1.1×	86 0.9×	111 1.5×	24	819
I. Ray-Coquard France	9	352 1.0×	437 1.9×	221 1.5×	114 1.2×	89 1.2×	28	712

Countries citing papers authored by Laura E. Horvath

Since Specialization

Citations

This map shows the geographic impact of Laura E. Horvath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura E. Horvath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura E. Horvath more than expected).

Fields of papers citing papers by Laura E. Horvath

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura E. Horvath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura E. Horvath. The network helps show where Laura E. Horvath may publish in the future.

Co-authorship network of co-authors of Laura E. Horvath

This figure shows the co-authorship network connecting the top 25 collaborators of Laura E. Horvath. A scholar is included among the top collaborators of Laura E. Horvath based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura E. Horvath. Laura E. Horvath is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

McWilliams, Robert R., Nathan R. Foster, Michelle R. Mahoney, et al.. (2017). North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic‐based dosing of irinotecan, oxaliplatin, and capecitabine as first‐line therapy for patients with advanced small bowel adenocarcinoma. Cancer. 123(18). 3494–3501. 31 indexed citations

Pandya, Bhavik J., Bruno C. Medeiros, Samuel Wilson, et al.. (2017). Quality of life of acute myeloid leukemia patients in a real-world setting.. Journal of Clinical Oncology. 35(15_suppl). e18525–e18525. 1 indexed citations

Davis, Lara E., Katherine A. Janeway, Aaron R. Weiss, et al.. (2017). Clinical trial enrollment of adolescents and young adults with sarcoma. Cancer. 123(18). 3434–3440. 25 indexed citations

D’Angelo, Sandra P., Michelle R. Mahoney, Brian Andrew Van Tine, et al.. (2017). A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401).. Journal of Clinical Oncology. 35(15_suppl). 11007–11007. 17 indexed citations

Medeiros, Bruno C., Bhavik J. Pandya, Samuel Wilson, et al.. (2017). Real-world prescribing patterns in acute myeloid leukemia in the United States.. Journal of Clinical Oncology. 35(15_suppl). e18524–e18524. 1 indexed citations

Dickson, Mark A., M. R. Mahoney, William D. Tap, et al.. (2016). Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma. Annals of Oncology. 27(10). 1855–1860. 90 indexed citations

Venook, Alan P., Donna Niedzwiecki, Federico Innocenti, et al.. (2016). Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).. Journal of Clinical Oncology. 34(15_suppl). 3504–3504. 246 indexed citations

Valdivieso, Manuel, Benjamin W. Corn, Janet Dancey, et al.. (2015). The Globalization of Cooperative Groups. Seminars in Oncology. 42(5). 693–712. 5 indexed citations

Denicoff, Andrea, Holly A. Massett, Rick Bangs, et al.. (2015). Creating a national collaborative strategy to enhance trial accrual in NCI’s National Clinical Trials Network (NCTN) in the era of precision medicine.. Journal of Clinical Oncology. 33(15_suppl). 6589–6589. 2 indexed citations

10.

Luke, Jason J., Jacob B. Allred, Laura E. Horvath, et al.. (2015). Randomized phase II study comparing the MET inhibitor cabozantinib to temozolomide (TMZ) or dacarbazine (DTIC) in ocular melanoma: A091201.. Journal of Clinical Oncology. 33(15_suppl). TPS9087–TPS9087. 1 indexed citations

11.

Ho, Alan L., Nathan R. Foster, Jeffrey P. Meyers, et al.. (2015). Alliance A091104: A phase II trial of MK-2206 in patients (pts) with progressive, recurrent/metastatic adenoid cystic carcinoma.. Journal of Clinical Oncology. 33(15_suppl). 6039–6039. 12 indexed citations

12.

Dickson, Mark A., Michelle R. Mahoney, William D. Tap, et al.. (2014). Alliance A091102: Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.. Journal of Clinical Oncology. 32(15_suppl). 10527–10527. 2 indexed citations

13.

Horvath, Laura E., Theresa L. Werner, Kenneth M. Boucher, & Kimberly Jones. (2013). The relationship between tumor size and stage in early versus advanced ovarian cancer. Medical Hypotheses. 80(5). 684–687. 20 indexed citations

14.

Horvath, Laura E., et al.. (2010). Multidisciplinary Care in the Oncology Setting: Historical Perspective and Data From Lung and Gynecology Multidisciplinary Clinics. Journal of Oncology Practice. 6(6). e21–e26. 72 indexed citations

15.

George, Sarah J., Laura E. Horvath, Robert E. Molokie, et al.. (2004). Response to Therapy with Imatinib Mesylate in Patients with CML Is Poor in Non-Caucasian Patients.. Blood. 104(11). 2937–2937. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact